[CCoE Notice] CPRIT’s Academic Research Program Releases Cycle 21.2 RFAs

Thu Aug 13 09:05:26 CDT 2020

Email not displaying correctly? View it in your browser<https://urldefense.com/v3/__https:/mailchi.mp/cprit/cprits-academic-research-program-releases-cycle-212-rfas?e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiDmeN8sQ$>
[https://urldefense.com/v3/__https://gallery.mailchimp.com/9bc46acc55c4a42d93566d3a5/images/5a182187-85f2-4aa9-94a5-29122c79320d.png__;!!LkSTlj0I!RyeUC6A0cA9fRQn5fDLsVNmttTKFuhV0n5hvSSwSx_wzbUAFoQwlXALd0N7ys61gz30$ ]<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/track/click?u=9bc46acc55c4a42d93566d3a5&id=dbca238c67&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiMq8j_rB$>
CPRIT announces the release of six (6) RFAs for the Academic Research program. Complete RFAs and instructions detailing applicable deadlines and requirements are available in the Apply for Funding<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/track/click?u=9bc46acc55c4a42d93566d3a5&id=662b2e02d9&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiPLxftUt$> section of CPRIT’s website<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/track/click?u=9bc46acc55c4a42d93566d3a5&id=b6abc022a7&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiP4L4WUE$>.

  *   Core Facility Support Awards (RFA-R 21.2 CFSA)
  *   Clinical Trials Network Award (RFA R-21.2 CTNA) NEW!
  *   Early Clinical Investigator Award (RFA-R-21.2 ECI)
  *   High Impact/High Risk Research Awards (HIHR) (RFA R-21.2 HIHR)
  *   Texas Clinical Trials Participation Program Award (RFA R-21.2 TCTPA) NEW!
  *   Texas Regional Excellence in Cancer Award (RFA R-21.2 TREC) NEW!
The application period is September 16, 2020 through January 27, 2021. Proposals must be submitted through CPRIT’s online grant application system<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/track/click?u=9bc46acc55c4a42d93566d3a5&id=062f6a1b9d&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiDJ_f9rC$>.
Core Facility Support Awards (RFA R-21.2-CFSA)
Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer. Institutions may submit 2 applications provided that 1 exclusively supports childhood cancer research.
Award: Up to $4,000,000 (total costs); Maximum duration: 5 years.
Clinical Trials Network Award (RFA R-21.2 CTNA)
The Clinical Trials Network Award will be made to an institution, organization, or physician group with an established clinical trials infrastructure and clinical trials portfolio to develop and oversee a network of two cancer care facilities that lack adequate access to clinical trials or sufficient clinical trials infrastructure (stage 1). Once an initial network is satisfactorily demonstrated, the program will be eligible to expand its network to two additional facilities located outside its current catchment (stage 2).
Award: Up to $600,000 annually for stage 1 and up to $900,000, annually for stage 2. Maximum duration: 4 years.
Early Clinical Investigator Award (ECI R-21.2 ECI)
Solicits applications from institutions to provide cancer physicians within the first 3 years of a faculty appointment as an assistant professor the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become successful clinical investigators. The award will protect time from clinical responsibilities to allow the early clinical investigator to develop and conduct investigator initiated clinical trials and to establish a partnership with a laboratory-based collaborator in order to design and conduct correlative studies needed to interpret the outcome of an interventional trial. The overall goal of this mechanism is to increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, capitalizing on basic discoveries and translating them through conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer. Institutions may submit up to 2 applications.
Award: Up to $1,500,000 (total costs); Maximum duration: 5 years.
High Impact/High Risk Research Awards (RFA R-21.2 HIHR)
Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers. Institutions may submit up to 5 applications
Award: Up to $250,000 (total costs); Maximum duration: 2 years.
Texas Clinical Trials Participation Program Award (RFA R-21.2 TCTPA)
Solicits applications targeting projects to increase the number and diversity of subjects participating in therapeutic cancer clinical trials in Texas by removing non-clinical out of pocket costs as barriers to participation in cancer clinical trials for financially burdened subjects. Institutions or organizations conducting clinical trials are restricted to 1 application.
Award: Up to $1,500,000 (total costs); Maximum duration: 3 years.
Texas Regional Excellence in Cancer Award (RFA R-21.2 TREC)
Solicits applications to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer reviewed cancer research funding. This mechanism is open to Texas institutions whose campus is located > 100 mi from an NCI Designated Cancer Center. The award will support an established investigator to lead a program with a cohesive theme relevant to the cancer problems of the region and 3 to 5 research projects. In addition, funds maybe requested to support recruitment of new junior faculty, shared resources, and partnerships with established Texas cancer research programs to provide mentorship and access to facilities or expertise.
Award: Up to $6,000,000 (total costs); Maximum duration: 5 years.
Copyright © 2020 Cancer Prevention and Research Institute of Texas<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/track/click?u=9bc46acc55c4a42d93566d3a5&id=155abc8270&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiFnv2pgg$>, All rights reserved.

Our mailing address is:
Cancer Prevention and Research Institute of Texas
PO Box 12097
Austin, Texas 78711

unsubscribe from this list<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/unsubscribe?u=9bc46acc55c4a42d93566d3a5&id=1092b2dc1b&e=9416b59a0d&c=6bccbf55bc__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiA-3ONu3$>    update subscription preferences<https://urldefense.com/v3/__https:/texas.us1.list-manage.com/profile?u=9bc46acc55c4a42d93566d3a5&id=1092b2dc1b&e=9416b59a0d__;!!LkSTlj0I!QzNoNgk6hLgMbNqgGoSv7O2zs8i4GKImdKmtfuPHV2FL_Wh0QrRVdUQyiD7t0pNW$>

-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://Bug.EGR.UH.EDU/pipermail/engi-dist/attachments/20200813/8901a025/attachment-0001.html 